The patient did not receive any medication known to alter the pharmacokinetics of levofloxacin. During levofloxacin treatment, renal function improved (creatinine clearance ¼102.3 mL/min) and glucose levels were unchanged. No electrocardiographic abnormalities or any adverse effect related to levofloxacin administration were found. The patient received this dose of intravenous levofloxacin for a total of 6 days, followed by oral levofloxacin at 500 mg/12 h for an additional 4 days. Clinical cure of the respiratory infection was rapidly achieved and the patient was discharged.
1
Regarding pharmacodynamic parameters, an AUC 0 -24 /MIC ratio of 143.27 was achieved, a value that exceeds the optimal ratio for favourable outcomes in patients with S. pneumoniae infections. 7 In conclusion, an intravenous levofloxacin dose of 750 mg/ 12 h (4 mg/kg/12 h) in our patient with morbid obesity achieved double the adult exposure following a standard dose of 750 mg per day to non-obese healthy volunteers. Consequently, it could be queried whether it is necessary to administer higher body weight-adjusted doses of levofloxacin in this population.
Additionally, the observed longer t 1/2 , resulting from an increase in V, suggests that it would be suitable to administer an initial loading dose to achieve the steady state rapidly, but followed by the administration of doses given less frequently than 12 hourly in order to avoid further drug accumulation. Nevertheless, these findings should be confirmed with further pharmacokinetic studies including a higher number of patients to ensure efficacy and avoid dose-related toxicity.
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None to declare. Sir, Cerebral toxoplasmosis remains one of the AIDS-defining events associated with the highest mortality. 1 The disease remains challenging despite the striking decrease in its incidence associated with the advent of highly active antiretroviral therapy (HAART). 2 We report a case of relapse of cerebral toxoplasmosis despite conventional secondary prophylaxis, which relies on half-dose pyrimethamine and sulfadiazine until immune status has been restored for 6 months. 3 A slight decrease in CD4+ T cell proportion was the only announcing event, whereas initial Toxoplasma strain typing (type II) and ongoing virological response were reassuring. This report should raise awareness of the possible failure of the conventional strategy, and of the importance of all available parameters in assessing residual risk.
An adult patient was diagnosed with asymptomatic HIV infection in early 2009. Antiretroviral treatment with tenofovir, emtricitabine and boosted darunavir was initiated because of low CD4 count (91 cells/mm 3 ). Four months later, the patient presented with headache, asthenia, behaviour changes and weight loss. Cerebral toxoplasmosis was diagnosed because of characteristic lesions on cerebral MRI examination, severe immunodeficiency (CD4 count 120 cells/mm 3 ), bad observance of co-trimoxazole prophylaxis and good response to pyrimethamine (100 mg on the first day then 75 mg/day), folinic acid (25 mg/day) and sulfadiazine (6 g/day) for 6 weeks. Toxoplasma serology showed a high titre of anti-Toxoplasma specific IgG antibodies (6043 IU/mL) and no specific IgM antibodies. Secondary prophylaxis of pyrimethamine (25 mg/day, associated with folinic acid) and sulfadiazine (2 g/day) was administered thereafter. No other opportunistic infection was diagnosed.
Under HAART, CD4 count rose above 200 cells/mm 3 (22% of T cells) and viral load became undetectable from the end of 2009 (Figure 1) . Consequently, secondary prophylaxis was stopped after 7 months. Four weeks after this interruption, the patient presented again with headache, asthenia and aphasia. Viral load was still undetectable, and CD4 count was 324 cells/mm 3 (18% of T cells). The titre of anti-Toxoplasma IgG antibodies was high, though lower than 1 year earlier (1622 IU/mL). Unfortunately, no serology had been performed in the meantime. Low titres of IgA specific antibodies were detected, suggesting parasitic reactivation. Cerebral MRI examination showed new lesions characteristic of cerebral toxoplasmosis. Because of the good immune status, stereotaxic biopsy was performed. Real-time PCR detected a high load of Toxoplasma gondii DNA in the cerebral biopsy. Microsatellite typing identified a type II strain. Pathological examination showed a polymorphic inflammatory infiltrate. There was no infiltration with CD8+ T lymphocytes evocative of immune reconstitution inflammatory syndrome, and no tumoral proliferation. The patient was treated again with full-dose pyrimethamine and sulfadiazine, and quickly presented clinical and radiological improvement.
Cerebral toxoplasmosis has been commonly described in patients suffering from AIDS, especially before the introduction of HAART.
2,3 Clinical disease is rare among patients with CD4 count .200 cells/mm 3 , and the greatest risk occurs among patients with a CD4 count of ,50 cells/mm 3 . 3 Though rare cases have been reported in patients with up to 408 CD4+ T cells/mm 3 , they were mostly diagnosed only by clinical and radiological criteria. 4, 5 To our knowledge, we report the first case of parasitological documentation of cerebral toxoplasmosis in a patient with .300 CD4+ T cells/mm 3 . More interestingly, failure of conventional secondary prophylaxis for cerebral toxoplasmosis in patients with AIDS has been reported only a few times before. Previous reports relied on presumptive diagnoses, and were associated with a decrease in CD4+ T lymphocyte count or percentage below thresholds of prophylaxis discontinuation. 5 International guidelines indeed recommend maintaining treatment with half-dose pyrimethamine and sulfadiazine until CD4 count is .200 cells/mm 3 (and 15% of total lymphocytes) for 6 months. 3 This strategy was not able to prevent relapse in this case. This failure did not appear to be related to specific parasitic features, as microsatellite typing established a type II Toxoplasma strain, which is predominant in Europe, and not one of the more virulent types that are more common in other parts of the world. Additionally, no evidence suggested decreased parasitic susceptibility to the drugs used for secondary prophylaxis, as curative treatment using the same drugs proved effective. It is noteworthy that neither viral response nor CD4 count heralded the relapse. The only preceding event was the diminution of CD4+ T cell proportion to ,20%.
Restoration of a T. gondii-specific T cell response (such as in vitro lymphocyte proliferative response and interferon-g production in response to T. gondii soluble antigen extract) was shown in patients increasing their CD4 counts under HAART after cerebral toxoplasmosis. 6 However, the time necessary to restore specific immunity has not been established. Indeed, some studies suggested that this may occur after 12 -18 months of successful HAART. 6, 7 Thus, stopping prophylaxis earlier might result in toxoplasmosis relapse in specific patients. However, this seems to be very uncommon, so the recommended strategy appears safe overall. Interestingly, high titres of anti-T. gondii IgG antibodies might not be associated with lymphocyte proliferative response to soluble antigen extract. 7 
